Contemporary outcomes after treatment of aberrant subclavian artery and Kommerell's diverticulum
- PMID: 36657501
- DOI: 10.1016/j.jvs.2023.01.014
Contemporary outcomes after treatment of aberrant subclavian artery and Kommerell's diverticulum
Abstract
Objective: Aberrant subclavian artery (ASA) and Kommerell's diverticulum (KD) are rare vascular anomalies that may be associated with lifestyle-limiting and life-threatening complications. The aim of this study is to report contemporary outcomes after invasive treatment of ASA/KD using a large international dataset.
Methods: Patients who underwent treatment for ASA/KD (2000-2020) were identified through the Vascular Low Frequency Disease Consortium, a multi-institutional collaboration to investigate uncommon vascular disorders. We report the early and mid-term clinical outcomes including stroke and mortality, technical success, and other operative outcomes including reintervention rates, patency, and endoleak.
Results: Overall, 285 patients were identified during the study period. The mean patient age was 57 years; 47% were female and 68% presented with symptoms. A right-sided arch was present in 23%. The mean KD diameter was 47.4 mm (range, 13.0-108.0 mm). The most common indication for treatment was symptoms (59%), followed by aneurysm size (38%). The most common symptom reported was dysphagia (44%). A ruptured KD was treated in 4.2% of cases, with a mean diameter of 43.9 mm (range, 18.0-100.0 mm). An open procedure was performed in 101 cases (36%); the most common approach was ASA ligation with subclavian transposition. An endovascular or hybrid approach was performed in 184 patients (64%); the most common approach was thoracic endograft and carotid-subclavian bypass. A staged operative strategy was employed more often than single setting repair (55% vs 45%). Compared with endovascular or hybrid approach, those in the open procedure group were more likely to be younger (49 years vs 61 years; P < .0001), female (64% vs 36%; P < .0001), and symptomatic (85% vs 59%; P < .0001). Complete or partial symptomatic relief at 1 year after intervention was 82.6%. There was no association between modality of treatment and symptom relief (open 87.2% vs endovascular or hybrid approach 78.9%; P = .13). After the intervention, 11 subclavian occlusions (4.5%) occurred; 3 were successfully thrombectomized resulting in a primary and secondary patency of 95% and 96%, respectively, at a median follow-up of 39 months. Among the 33 reinterventions (12%), the majority were performed for endoleak (36%), and more reinterventions occurred in the endovascular or hybrid approach than open procedure group (15% vs 6%; P = .02). The overall survival rate was 87.3% at a median follow-up of 41 months. The 30-day stroke and death rates were 4.2% and 4.9%, respectively. Urgent or emergent presentation was independently associated with increased risk of 30-day mortality (odds ratio [OR], 19.8; 95% confidence interval [CI], 3.3-116.6), overall mortality (OR, 3.6; 95% CI, 1.2-11.2) and intraoperative complications (OR, 8.3; 95% CI, 2.8-25.1). Females had a higher risk of reintervention (OR, 2.6; 95% CI, 1.0-6.5). At an aneurysm size of 44.4 mm, receiver operator characteristic curve analysis suggested that 60% of patients would have symptoms.
Conclusions: Treatment of ASA/KD can be performed safely with low rates of mortality, stroke and reintervention and high rates of symptomatic relief, regardless of the repair strategy. Symptomatic and urgent operations were associated with worse outcomes in general, and female gender was associated with a higher likelihood of reintervention. Given the worse overall outcomes when symptomatic and the inherent risk of rupture, consideration of repair at 40 mm is reasonable in most patients. ASA/KD can be repaired in asymptomatic patients with excellent outcomes and young healthy patients may be considered better candidates for open approaches versus endovascular or hybrid modalities, given the lower likelihood of reintervention and lower early mortality rate.
Keywords: Aberrant subclavian artery; Kommerell's diverticulum.
Copyright © 2023 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.
Similar articles
-
International Multi-Institutional Experience with Presentation and Management of Aortic Arch Laterality in Aberrant Subclavian Artery and Kommerell's Diverticulum.Ann Vasc Surg. 2023 Sep;95:23-31. doi: 10.1016/j.avsg.2023.05.005. Epub 2023 May 24. Ann Vasc Surg. 2023. PMID: 37236537
-
Mid-Term Results of Treating Kommerell's Diverticulum and Aberrant Subclavian Artery Anomalies Using a Patient-Centered Team Approach.Vasc Endovascular Surg. 2023 Jul;57(5):504-512. doi: 10.1177/15385744231154082. Epub 2023 Jan 23. Vasc Endovascular Surg. 2023. PMID: 36689395
-
A systematic review of open, hybrid, and endovascular repair of aberrant subclavian artery and Kommerell's diverticulum treatment.J Vasc Surg. 2023 Feb;77(2):642-649.e4. doi: 10.1016/j.jvs.2022.07.010. Epub 2022 Jul 15. J Vasc Surg. 2023. PMID: 35850164 Review.
-
Safety and efficacy of a hybrid approach for repair of complicated aberrant subclavian arteries.J Vasc Surg. 2020 Dec;72(6):1873-1882. doi: 10.1016/j.jvs.2020.01.075. Epub 2020 Jul 19. J Vasc Surg. 2020. PMID: 32665182
-
Hybrid repair of symptomatic aberrant right subclavian artery and Kommerell's diverticulum.Ann Vasc Surg. 2014 Feb;28(2):411-20. doi: 10.1016/j.avsg.2013.04.016. Epub 2013 Nov 5. Ann Vasc Surg. 2014. PMID: 24200134 Review.
Cited by
-
Thoracic Endovascular Aortic Repair Without Subclavian Revascularization of a Ruptured Kommerell Diverticulum.JACC Case Rep. 2024 Apr 22;29(11):102349. doi: 10.1016/j.jaccas.2024.102349. eCollection 2024 Jun 5. JACC Case Rep. 2024. PMID: 38665999 Free PMC article.
-
Surgical repair of severe dysphagia lusoria.J Vasc Surg Cases Innov Tech. 2023 Jul 17;9(3):101265. doi: 10.1016/j.jvscit.2023.101265. eCollection 2023 Sep. J Vasc Surg Cases Innov Tech. 2023. PMID: 37662575 Free PMC article.
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical